They also demonstrated, using a mouse model, that therapeutic co-administration of anti-TGF-β and anti-PD-L1 blocking antibodies reduced TGF-β signaling in stromal cells, allowing the release of TGF-β in the tumor center that promoted an anti-tumor immune response and tumor regression [253]. This evidence concerns the gene CD274 and neoplasm.